Figure 1.
Investigator-assessed PFS overall. ∗HR based on stratified Cox proportional hazards model; †P value based on stratified log-rank test. ‡HR based on unstratified Cox proportional hazards model; §P value based on unstratified log-rank test. A, acalabrutinib; Clb, chlorambucil; O, obinutuzumab.

Investigator-assessed PFS overall. ∗HR based on stratified Cox proportional hazards model; †P value based on stratified log-rank test. ‡HR based on unstratified Cox proportional hazards model; §P value based on unstratified log-rank test. A, acalabrutinib; Clb, chlorambucil; O, obinutuzumab.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal